First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults (clinicaltrials.gov) - Jun 6, 2025 - P1 | N=160 | Completed | Sponsor: Clover Biopharmaceuticals AUS Pty | Recruiting ➔ Completed | N=60 ➔ 160 | Trial primary completion date: Oct 2024 ➔ Feb 2025
Enrollment change • Trial completion • Trial primary completion date • Respiratory Diseases • Respiratory Syncytial Virus Infections
|